| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
AC-55649 targets the retinoic acid receptor beta 2 (RARβ2), a nuclear receptor that regulates gene expression in response to retinoic acid. RARβ2 is involved in various physiological processes, including cell differentiation, proliferation, and apoptosis. AC-55649 is a highly isoform-selective agonist that specifically activates RARβ2 with a pEC50 of 6.9. Its selectivity for RARβ2 over other RAR isoforms makes it a valuable tool for studying the specific functions of RARβ2.
|
|---|---|
| ln Vitro |
AC-55649 is a strong, highly isoform-selective agonist with a pEC50 of 6.9 for the human RARβ2 receptor[1]. The transcriptional activity of RARβ2 is strongly and selectively activated by AC-55649 [2].
In vitro, AC-55649 is a potent and selective activator of RARβ2 transcriptional activity. It has a pEC50 of 6.9 for the human RARβ2 receptor. The compound demonstrates high isoform selectivity, potently activating RARβ2 while showing reduced activity at other RAR isoforms. AC-55649's transcriptional activity has been confirmed in reporter gene assays. The compound is soluble in DMSO at 90.0 mg/mL (289.9 mM). |
| ln Vivo |
In vivo data for AC-55649 are limited in publicly available sources. As a potent and selective RARβ2 agonist, the compound has potential applications in studying RARβ2-mediated physiological processes. The compound is described as a potent, highly isoform-selective agonist, suggesting that it may have in vivo activity. However, specific in vivo efficacy data from animal models are not extensively reported.
|
| Enzyme Assay |
In non-cell-based receptor binding assays, AC-55649's affinity for RARβ2 is evaluated using radioligand competition binding experiments. Nuclear receptor preparations or purified RAR proteins are incubated with a radiolabeled RAR ligand and varying concentrations of AC-55649. After incubation, bound and free radioligand are separated, and radioactivity is measured. Competition curves are generated to determine IC50 and Ki values, confirming the compound's potent binding affinity for RARβ2.
|
| Cell Assay |
In vitro cellular assays for AC-55649 involve measuring its agonist activity at RARβ2 using reporter gene assays. Cells are transfected with a reporter construct containing a retinoic acid response element (RARE) upstream of a luciferase or other reporter gene, along with expression constructs for RARβ2 and its heterodimer partner RXR. Cells are treated with AC-55649, and reporter activity is measured to quantify RARβ2 activation. These assays have established AC-55649's pEC50 of 6.9 and its selectivity profile.
|
| Animal Protocol |
In vivo animal studies for AC-55649 have not been extensively reported in publicly available sources. As a RARβ2 agonist, the compound would be expected to be evaluated in animal models relevant to RARβ2 function. The compound is described as a potent agonist, suggesting that it may have been studied in preclinical models. However, specific protocols and data are limited.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic properties of AC-55649 are limited in publicly available sources. The compound is soluble in DMSO at 90.0 mg/mL (289.9 mM) and in ethanol at 25 mM. Storage conditions for the powder are -20°C for 3 years; in solvent, it can be stored at -80°C for 1 year. As a small molecule RARβ2 agonist, it is expected to have reasonable oral bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicological data for AC-55649 are limited in publicly available sources. As a research compound intended for laboratory use, comprehensive toxicology studies have not been extensively published. The compound is not intended for human use and should be handled with appropriate safety precautions. Its safety profile is consistent with that of other research chemicals used in preclinical studies.
|
| References | |
| Additional Infomation |
4-(4-Octylphenyl)benzoic acid belongs to the biphenyl class of compounds and is a carboxylated biphenyl.
AC-55649 is a potent, highly isoform-selective agonist of the human RARβ2 receptor with a pEC50 of 6.9. It is a potent and selective activator of RARβ2 transcriptional activity. The compound is a research chemical used to study the role of RARβ2 in various biological processes. It is not an approved drug and is intended for research use only. |
| Molecular Formula |
C21H26O2
|
|---|---|
| Molecular Weight |
310.42994
|
| Exact Mass |
310.193
|
| Elemental Analysis |
C, 81.25; H, 8.44; O, 10.31
|
| CAS # |
59662-49-6
|
| PubChem CID |
1714884
|
| Appearance |
White to off-white solid powder
|
| Density |
1.037g/cm3
|
| Boiling Point |
462ºC at 760 mmHg
|
| Flash Point |
216.9ºC
|
| Index of Refraction |
1.548
|
| LogP |
5.954
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
23
|
| Complexity |
323
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=CC=C(C2=CC=C(CCCCCCCC)C=C2)C=C1)O
|
| InChi Key |
HXBKPYIEQLLNBK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H26O2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)19-13-15-20(16-14-19)21(22)23/h9-16H,2-8H2,1H3,(H,22,23)
|
| Chemical Name |
4-(4-octylphenyl)benzoic acid
|
| Synonyms |
AC55649; AC-55649; AC 55649;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~322.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2213 mL | 16.1067 mL | 32.2134 mL | |
| 5 mM | 0.6443 mL | 3.2213 mL | 6.4427 mL | |
| 10 mM | 0.3221 mL | 1.6107 mL | 3.2213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
